Herpes zoster - I-Herpes Zoster
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Herpes zoster amabhamuza entanyeni nasehlombe
References
Ama-shingles, okubangelwa ukuvuselelwa kwegciwane le-varicella zoster elibhekene nenkukhu, lithinta cishe abantu abayizigidi ezingu-1 ngonyaka e-United States, ngengozi yokuphila yonke engama-30%. Labo abanamasosha omzimba abuthakathaka bathambekele kakhulu ekubeni nama-shingles, nezimpawu ngokuvamile eziqala ngokuba nokungalungi, ikhanda elibuhlungu, nomkhuhlane omncane, okulandelwa ukuzwela kwesikhumba okungavamile ezinsukwini ezimbalwa ngaphambi kokuvela kokuqubuka. Lokhu kuqubuka, okuvamise ukuvela endaweni ethile yomzimba, kuqhubekela phambili kusuka kumabhamuza acwebile kuye ezilonda eziqinile phakathi nesonto kuye ezinsukwini eziyishumi. Ukwelashwa ngokushesha ngemithi elwa namagciwane (acyclovir, valacyclovir, or famciclovir) phakathi kwamahora angu-72 okuqala ukuqubuka kubalulekile. I-postherpetic neuralgia, inkinga evamile ebonakala ngobuhlungu besikhathi eside endaweni ethintekile, ithinta cishe isiguli esisodwa kweziyisihlanu futhi idinga ukuphathwa okuqhubekayo ngemithi efana ne-gabapentin, i-pregabalin, noma ama-antidepressants athile, kanye nama-topical agents afana ne-lidocaine noma i-capsaicin. Ukugonyelwa i-varicella zoster virus kuyanconywa kubantu abadala abaneminyaka engu-50 nangaphezulu ukuze kwehliswe ingozi ye-shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster ijwayele ukwenzeka kaningi kubantu abaneminyaka engu-50 nangaphezulu, labo abanamasosha omzimba abuthaka, nalabo abathatha imishanguzo ye-immunosuppressant. Ibangelwa ukuvuselelwa kwegciwane le-varicella-zoster, igciwane elifanayo elibangela inkukhu. Izimpawu ezinjengomkhuhlane, ubuhlungu, nokuluma ngokuvamile zandulela ukuqubuka kwesici. Inkinga evame kakhulu i-post-herpetic neuralgia, okuwubuhlungu obuqhubekayo bezinzwa ngemva kokuba ukuqubuka kuphelile. Izici zobungozi kanye nezinkinga ezihlobene ne-herpes zoster ziyahlukahluka kuye ngeminyaka, impilo yokuzivikela komzimba, kanye nesikhathi sokuqala kokwelashwa. Ukugonywa kwabantu abaneminyaka engu-60 nangaphezulu kukhonjiswe ukunciphisa kakhulu ukwenzeka kwe-herpes zoster kanye ne-post-herpetic neuralgia. Ukuqala imishanguzo elwa namagciwane kanye nezidambisi zobuhlungu phakathi namahora angu-72 okuqala ukuqubuka kunganciphisa ukuqina kanye nezinkinga ze-herpes zoster kanye ne-post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Izivivinyo zomtholampilo ngaphambi kokugunyazwa zibonisa ukuthi umuthi wokugomela i-live zoster usebenza cishe ku-50 kuya ku-70%, kuyilapho umgomo oyinhlanganisela usebenza kangcono, kusukela ku-90 kuya ku-97%. Ocwaningweni lwasemhlabeni wangempela, basekela okutholwe yizilingo, okubonisa ukuthi umgomo ophilayo cishe usebenza ngo-46%, kuyilapho ophinde wahlanganiswa cishe ucishe ube ngama-85%.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
I-Chickenpox, ebizwa nangokuthi i-varicella, ivela ekuthelelekeni kokuqala ngegciwane, okuvame ukwenzeka ngesikhathi sobuntwana noma sokuthomba. Uma i-chickenpox isiselaphekile, igciwane lingahlala lingasebenzi (lithule) emangqamuzaneni ezinzwa zomuntu iminyaka noma amashumi eminyaka, ngemva kwalokho lingase liphinde lisebenze. i-herpes zoster (herpes zoster) imiphumela uma i-varicella virus elele ivuselelwe. Khona-ke leli gciwane lihamba emizimbeni yezinzwa liye emaphethelweni ezinzwa esikhunjeni, likhiphe amabhamuza. Ngesikhathi sokuqubuka kwe- i-herpes zoster (herpes zoster) , ukuchayeka kugciwane le-varicella elitholakala kumabhamuza angu- i-herpes zoster (herpes zoster) kungabangela i-chickenpox kumuntu ongakabi nayo i-chickenpox.
Izinto eziyingozi zokuvuselela igciwane elilele zihlanganisa ukuguga, ukungasebenzi kahle kwamasosha omzimba, nokuba nesifo senkukhu ngaphambi kwezinyanga eziyi-18 ubudala. I-Varicella zoster virus ayifani negciwane le-herpes simplex, nakuba bobabili bengamalungu omndeni ofanayo we-herpesviruses.
Imithi yokugoma engu- i-herpes zoster (herpes zoster) yehlisa ubungozi be- i-herpes zoster (herpes zoster) ngo-50% ukuya ku-90%. Iphinde yehlise amazinga e-postherpetic neuralgia, futhi, uma i-herpes zoster (herpes zoster) yenzeka, ubukhali bayo. Uma i- i-herpes zoster (herpes zoster) iqala, imithi elwa namagciwane njenge-aciclovir inganciphisa ukuqina nobude besifo uma iqalwe phakathi namahora angu-72 kuvele ukuqubuka.
○ Ukwelashwa
Uma izilonda zisakazeka ngokushesha, bonana nodokotela wakho ngokushesha ngangokunokwenzeka ukuze uthole ukwelashwa ngezidambisigciwane.
Zombili izidakamizwa ezilwa namagciwane kanye ne-neuralgia ziyadingeka. Kufanele uphumule futhi uyeke ukuphuza utshwala.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin